Millennium Management LLC Sells 129,561 Shares of Natera, Inc. $NTRA

Millennium Management LLC cut its position in shares of Natera, Inc. (NASDAQ:NTRA) by 33.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 255,683 shares of the medical research company’s stock after selling 129,561 shares during the period. Millennium Management LLC owned approximately 0.19% of Natera worth $36,156,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in NTRA. LRI Investments LLC purchased a new stake in shares of Natera during the 4th quarter worth approximately $29,000. Bank of Jackson Hole Trust bought a new stake in Natera in the first quarter worth $29,000. Rakuten Securities Inc. increased its position in Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company’s stock worth $31,000 after purchasing an additional 119 shares during the last quarter. TCTC Holdings LLC raised its stake in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after purchasing an additional 124 shares in the last quarter. Finally, ORG Partners LLC bought a new position in Natera during the first quarter valued at $32,000. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

NTRA opened at $176.37 on Wednesday. The stock’s 50 day moving average price is $154.63 and its 200-day moving average price is $153.87. Natera, Inc. has a one year low of $114.62 and a one year high of $183.00. The stock has a market cap of $24.21 billion, a price-to-earnings ratio of -92.34 and a beta of 1.68.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The business had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the prior year, the business posted ($0.30) earnings per share. Natera’s revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. As a group, analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on NTRA shares. Cowen restated a “buy” rating on shares of Natera in a report on Friday, August 8th. Royal Bank Of Canada set a $268.00 price objective on Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Stephens restated an “overweight” rating and set a $183.00 price objective on shares of Natera in a research report on Friday, August 15th. Barclays reiterated an “overweight” rating and issued a $210.00 target price (up previously from $190.00) on shares of Natera in a report on Friday, August 8th. Finally, Morgan Stanley restated an “overweight” rating and set a $195.00 price target on shares of Natera in a report on Sunday, August 10th. One equities research analyst has rated the stock with a Strong Buy rating and seventeen have given a Buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $194.00.

Insider Buying and Selling at Natera

In related news, insider John Fesko sold 678 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $155.46, for a total value of $105,401.88. Following the transaction, the insider owned 152,747 shares of the company’s stock, valued at $23,746,048.62. This trade represents a 0.44% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 2,496 shares of Natera stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $133.17, for a total transaction of $332,392.32. Following the sale, the director owned 5,763 shares of the company’s stock, valued at $767,458.71. The trade was a 30.22% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.